COPENHAGEN, Aug 9 (Reuters) - Danish industrial enzymes maker Novozymes on Wednesday reported a bigger fall than expected in second-quarter profit and lowered its full-year sales guidance.

Operating profit landed at 865 million crowns ($127 million) against a year-earlier 1.11 billion and a mean forecast of 965 million in a poll of analysts published by Novozymes.

The group narrowed the range for its full-year sales growth expectation to 4-6% from 4-7%. It said second-quarter organic sales growth was 2%, driven by stronger sales at its Bioenergy division.

"We continue to expect a stronger second half supported by pipeline innovation, increased market penetration, and a softer comparator," CEO Ester Baiget said in a statement.

Novozymes in December agreed to take over Danish peer Chr. Hansen, with the companies expecting to complete the deal in the fourth quarter.

Chr. Hansen focuses on enzymes and microbials for the food sector while Novozymes' largest business areas include enzymes for household products, food and beverages and biofuels.

($1 = 6.7881 Danish crowns) (Reporting by Johannes Birkebaek, editing by Anna Ringstrom)